Thiazolidinediones: effects on insulin resistance and the cardiovascular system. - Wikidata - wikimedia - TriplyDB

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

http://www.wikidata.org/entity/Q36484662

about

PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer Enhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetes Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.Minireview: Pathophysiological roles of the TR4 nuclear receptor: lessons learned from mice lacking TR4 Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787.Adiponectin prevents diabetic premature senescence of endothelial progenitor cells and promotes endothelial repair by suppressing the p38 MAP kinase/p16INK4A signaling pathway.Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials.Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.The complexities of obesity and diabetes with the development and progression of pancreatic cancer.Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1 Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells.In vivo and in vitro evidence that PPARγ ligands are antagonists of leptin signaling in breast cancer Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status.ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis.PPARG, AGTR1, CXCL16 and LGALS2 polymorphisms are correlated with the risk for coronary heart disease.Pioglitazone treatment decreases follicular fluid levels of tumor necrosis factor-α and interleukin-6 in patients with polycystic ovary syndrome Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist.The Role of PPAR-gamma and Its Interaction with COX-2 in Pancreatic Cancer.Metabolic syndrome in Iranian youths: a population-based study on junior and high schools students in rural and urban areas.Phytochemicals Mediate the Expression and Activity of OCTN2 as Activators of the PPARγ/RXRα Pathway.The effect of exercise training combined with PPARγ agonist on skeletal muscle glucose uptake and insulin sensitivity in induced diabetic obese Zucker rats.Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies Molecular mechanisms involved in obesity-associated insulin resistance: therapeutical approach.Peroxisome proliferator-activated receptors and atherosclerosis.Tumor necrosis factor-α-induced inflammatory responses in cattle.Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?PPAR-γ agonist attenuates inflammation in aortic aneurysm patients.The use of Cox-2 and PPARγ signaling in anti-cancer therapies.Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin.Modulation of metabolic and cardiac dysfunctions by insulin sensitizers and angiotensin receptor blocker in rat model of type 2 diabetes mellitus.Palmitate-induced insulin resistance is attenuated by Pioglitazone and EGCG through reducing the gluconeogenic key enzymes expression in HepG2 cells.Peroxisome proliferator-activated receptor γ agonists attenuate hyperglycaemia-induced hyaluronan secretion in vascular smooth muscle cells by inhibiting PKCβ2.An MG53-IRS1-interaction disruptor ameliorates insulin resistance.

P2860

Q21328702-2A89B86F-5252-4C9D-8D5B-2B00D650AF78 Q28749389-A62E1162-72F9-4704-B94D-18FA4E06F7CF Q33603551-C26E5D68-5842-4B01-B2C2-D43EAE19AD7C Q33701419-434746C5-9150-4659-9102-C5C366E8D2E8 Q34128015-22E5A3AC-0676-433A-87A4-7A9D28F113FC Q34237779-C80E8E9C-D378-46E5-8C32-E7F166D32017 Q34287296-13AEC267-8314-4415-B1D3-8D6E73C4DA1D Q34397685-4B1DBE10-9FF9-4C12-BAEF-588BDEDD63F6 Q34442391-83639352-7926-45AC-A9D7-5F11320BD95A Q34669361-5E45A4BD-6851-4656-BFB7-D47E6432FA8A Q34996841-80BDAC81-D0BC-480B-9F4E-123CF087E159 Q35005663-4A5007C7-602E-43A4-A1BC-3EA02C5BD113 Q35168034-13D4282B-6FEE-45C6-90D6-47A30B2D439D Q35468539-59676FDC-D59B-419D-8427-3D4388A79ABF Q35555401-B1AE5F26-10B8-447E-9D28-F6CC6DEBD1D1 Q35629054-3C670969-7CD0-4DB3-9223-46356F9BE94C Q35632330-D63CF59F-A57F-4134-82AF-938AA38FC734 Q35767762-84569834-082C-4B5C-97F7-99FA43371147 Q35932449-CBEE4E82-6AD1-44AA-8C13-BEF9E06A0431 Q36179560-CDF6C448-E005-4457-808B-C27445C48415 Q36363679-340DFEAD-42C0-4313-8F4E-41EA5B46D2E0 Q36742740-6C5274AD-94D7-454D-BEF0-389849C9AB56 Q36931481-F7DF2849-7A55-479A-AD5E-114CE264BCD2 Q37048770-7DEBF97D-838A-40A0-B84A-7A15D3B846A4 Q37160834-426F88EA-1A11-4741-8C2D-48C0EAE7258E Q37182794-3011EA89-54AE-4BA7-AEAE-43C5C76B63B6 Q37578545-2CC3E879-01AE-40FC-B015-8250FEE26F1F Q37861955-18A4B829-89E8-4E08-BBD1-C8B3DEDD377A Q37906773-980D810D-A73A-48ED-9000-6D030F987931 Q37992099-7A6E24BA-AC05-4EB3-ADF4-A19AF31DE741 Q39575691-51FF6864-D2F4-408D-A7A6-9404398B93AC Q39740098-71CEEFC5-2FF1-40F3-BD26-0A742E0D165E Q40693751-2D1B35A1-2763-4463-BE91-D914D0950280 Q42116284-2DF2264D-2188-410F-9C61-06902C94BEC7 Q42379243-D97B620D-B99F-4DC2-BA7F-66679985CA0D Q45374016-B674692C-361E-4189-9215-0B4BD1ACD77C Q46361420-07EFC05A-390F-4288-BE60-CEF7F1DE4FFD Q49837836-4A7C3DCF-F701-4243-8CBE-0237E682BB4F Q54444900-5409DDD8-8EE1-4911-8A7E-FC2BD4135947 Q55400599-71567247-F7EF-42B7-A434-A3519DBBDC7B

P2860

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

http://www.wikidata.org/entity/Q36484662

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

@ast

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

@en

type

label

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

@ast

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

@en

prefLabel

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

@ast

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

@en

P1433

Q36484662-921D3F6B-040A-4011-9623-44F308A95329

P1476

Q36484662-FD9CC8A1-C333-4923-B53B-5F562496506F

P2093

Q36484662-1C5F306D-4FD0-4463-B2A8-092361DE3F05

Q36484662-2A3CCB87-C7AB-45C1-9419-5EF332F5C059

Q36484662-38F8D5FA-B022-4E79-86E0-052BFAF6DFCE

Q36484662-BF3EB81E-5026-4363-B366-BEC9F8B693F6

P2860

Q36484662-018DE30F-2FE6-44C5-99D1-360D20964446

Q36484662-03B7E5A2-C879-4880-ACAB-2587EF7E8A34

Q36484662-05C46B6A-18E7-4E15-B7D0-D654806C52BE

Q36484662-085D06BB-37B1-499A-BA86-746192111AC1

Q36484662-089081BB-42B2-4A6E-A1F7-BE3846BE1A38

Q36484662-0D876747-88DB-41ED-8E1F-AEC952BCEBCB

Q36484662-190DA940-F264-4E71-AE86-F53A133E6FA9

Q36484662-19F3A08E-8654-4E86-914B-B97659C48886

Q36484662-19F9741D-9A8C-4180-A563-80470F88DC04

Q36484662-20ED1497-504F-4F8A-951C-770993AAC333

P304

Q36484662-3709A06E-8B4C-42D9-87B4-60F7000F41C9

P31

Q36484662-40166457-262C-4277-962C-CE6C31C11CF9

P356

Q36484662-7D190312-A39F-4872-9B4C-6BC1E4CE780E

P407

Q36484662-3C20D6B8-0FAD-4E34-AB57-F9DD2976A801

P433

Q36484662-1A9D7323-D013-4B37-AAD2-A663C5C00EE6

P478

Q36484662-2ED4C5C9-8880-4994-A602-D3B757F8A528

P577

Q36484662-EB69B50A-93B9-4601-8E87-345AD8B9BBDD

P5875

Q36484662-CB0A798C-685B-42CC-A52A-3B8C94CE2E69

P698

Q36484662-65034B39-B411-4700-A6C7-02693CCD0878

P932

Q36484662-C8064874-9D6E-4032-AEDD-74979766A75E

P356

P1433

British Journal of Pharmacology

P1476

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

@en

P2093

C E Quinn

http://www.w3.org/2001/XMLSchema#string

C J Lockhart

http://www.w3.org/2001/XMLSchema#string

G E McVeigh

http://www.w3.org/2001/XMLSchema#string

P K Hamilton

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

Mechanism of free fatty acid-induced insulin resistance in humans

Atherosclerosis — An Inflammatory Disease

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Obesity is associated with macrophage accumulation in adipose tissue

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

The mechanisms of action of PPARs

The organization, promoter analysis, and expression of the human PPARgamma gene

Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics

P304

636-645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0707452

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

153

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5937642

http://www.w3.org/2001/XMLSchema#string

P698

17906687

http://www.w3.org/2001/XMLSchema#string

P932

2259217

http://www.w3.org/2001/XMLSchema#string